Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 The association between chemotherapy regimen, relapse status, and WEnCA result in 88 stage III CRC patients

From: Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array

Chemotherapy regimen (N) WEnCA (N) Relapse No relapse P-value
  N = 42 (%) N = 46 (%)  
FOLFOX-4 plus Cetuximab (N = 59) Positive (N = 8) 6 (75) 2 (25) 0.047
  Negative (N = 51) 17 (33.3) 34 (66.7)  
FOLFOX-4 (N = 29) Positive (N = 6) 3 (50) 3 (50) 0.633
  Negative (N = 23) 16 (48.5) 7 (21.2)